Betta Pharmaceuticals

Betta Pharmaceuticals Co., Ltd. develops, manufactures, and commercializes innovative oncology drug therapies. Its core product, Icotinib hydrochloride (Conmana®), is China's first small molecule anti-cancer drug for EGFR-targeted therapy. The company maintains a robust pipeline, including Ensartinib for non-small cell lung cancer (NSCLC) and Vorolanib for renal cell carcinoma, driven by integrated R&D capabilities in targeted therapeutics.

Dr. Lieming Ding founded Betta Pharmaceuticals in 2003 to create indigenous innovative drug solutions. An M.D. and U.S.-certified pathologist, Dr. Ding leveraged his scientific expertise to lead Icotinib's development, establishing China’s first domestically produced small molecule targeted therapy for lung cancer. This initiative addressed critical unmet needs within the therapeutic landscape.

Betta Pharmaceuticals serves cancer patients, providing novel therapeutic options for diseases like NSCLC. The company envisions continuous R&D investment for severe diseases, aiming for global expansion. With products like Ensartinib under FDA review, Betta seeks to broaden international patient access to its Chinese-developed innovative medicines, advancing oncology care.